

Infective Endocarditis as the Cause of Death: A Population-based Study in Portugal, from 2002 to 2018

Endocardite Infeciosa Como Causa de Morte: Um Estudo Populacional em Portugal, de 2002 a 2018



Catarina de SOUSA^{1,2}, Ruy M. RIBEIRO³, Fausto J. PINTO^{1,4}
Acta Med Port 2021 34(AOP) - <https://doi.org/10.20344/amp.14609>

ABSTRACT

Introdução: Infective endocarditis presents a high rate of morbidity and mortality. Population-based studies addressing mortality caused by infective endocarditis in Portugal are scarce. We aimed to study deaths caused by Infective endocarditis, as well as corresponding demographics and temporal trends.

Material and Methods: Retrospective cohort study of all patients whose main cause of death was Infective endocarditis in Portugal from 2002 to 2018. The data was obtained from the national death certificate information system.

Results: In Portugal, 3634 people died from infective endocarditis throughout the 17-year study period - infective endocarditis specific mortality rate of 2.1 per 100 000 habitants. Of all deceased, 89% were at least 60 years old, and most were women (55%). Overall, 72% died in a healthcare institution. An annual 9% increase in the incidence death rate from Infective endocarditis was observed, with a significant upward trend during the colder months.

Discussion: In Portugal, mortality by infective endocarditis increased, mainly affecting older patients and women, and which can partially be explained by factors such as ageing of the population. The management of older patients with infective endocarditis is challenging as they present a higher number of comorbidities, more valvular heart disease and valve implants, invasive medical procedures and are less likely to undergo cardiac surgery.

Conclusion: In addition to data on the evolution of demographics in Portugal, it is crucial to study the incidence of infective endocarditis over time to help explain these findings. The identification of factors that can be used to better model national health policies to improve clinical outcomes of infective endocarditis in Portugal is also required.

Keywords: Endocarditis/epidemiology; Endocarditis/mortality; Portugal; Seasons

RESUMO

Introdução: A endocardite infecciosa apresenta uma taxa substancial de morbilidade e mortalidade. Estudos populacionais que abordam a mortalidade por endocardite infecciosa em Portugal são escassos. O nosso objetivo foi estudar as mortes causadas por endocardite infecciosa e os dados demográficos e tendências temporais correspondentes.

Material e Métodos: Estudo de coorte retrospectivo de todos os doentes cuja causa de óbito foi endocardite infecciosa em Portugal entre 2002 e 2018. Os dados foram obtidos no sistema nacional de informação de certificados de óbito.

Resultados: Em Portugal, 3634 pessoas morreram de endocardite infecciosa ao longo de um período de 17 anos - taxa de mortalidade específica da endocardite infecciosa de 2,1 por 100 000 habitantes. De todos os falecidos, 89% tinham pelo menos 60 anos, a maior parte dos quais do género feminino (55%) e morreram por endocardite infecciosa. Globalmente, 72% morreram numa instituição de saúde. Foi demonstrado um aumento anual de 9% na taxa de mortalidade por endocardite infecciosa, com uma tendência ascendente significativa nos meses mais frios.

Discussão: Em Portugal, a mortalidade por endocardite infecciosa aumentou, afetando principalmente doentes mais idosos e mulheres, o que pode ser parcialmente explicado pelo envelhecimento da população. O manejo de doentes idosos com endocardite infecciosa é exigente, pois apresentam maior número de comorbidades, mais valvulopatia e próteses valvulares, procedimentos médicos invasivos e menor probabilidade de serem submetidos a cirurgia cardíaca.

Conclusão: Para além dos dados sobre a evolução demográfica de Portugal, é indispensável rever a incidência da endocardite infecciosa e a sua tendência, de forma a melhor interpretar estes resultados. É fundamental identificar indicadores que possam ser usados para melhor modelar as políticas nacionais de saúde, de forma a melhorar os resultados clínicos na endocardite infecciosa no nosso país.

Palavras-chave: Endocardite/epidemiologia; Endocardite/mortalidade; Estações; Portugal

INTRODUCTION

Infective endocarditis (IE), an inflammatory process affecting the valves, endocardium and/or intracardiac prosthetic material, and is often caused by bacteria. A high incidence of morbidity and mortality related to complicated IE has been described.¹

Worldwide, IE has an estimated annual incidence rate of 3 - 10 per 100 000 people.² Several studies³⁻⁶ reported an increasing incidence over time. This is likely due to an ageing population, as well as other factors such as a higher

1. Centro Cardiovascular da Universidade de Lisboa (CCUL). Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal.

2. Serviço de Cardiologia. Centro Hospitalar Barreiro/Montijo (CHBM). Barreiro. Portugal.

3. Laboratório de Biomatemática. Instituto de Saúde Ambiental. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal.

4. Departamento Coração e Vasos. Centro Hospitalar e Universitário Lisboa Norte (CHULN). Lisboa. Portugal.

✉ Autor correspondente: Catarina Sousa. catarinasousacardio@gmail.com

Recebido: 21 de julho de 2020 - Aceite: 24 de janeiro de 2021 - First published: 08 de março de 2021

Copyright © Ordem dos Médicos 2021



prevalence of structural valve disease, prosthetic valves or intracardiac devices and comorbidities (diabetes, hemodialysis, HIV) or a high rate of invasive medical procedures.

Despite improvement in diagnosis and medical/surgical treatment, most centers report an intrahospital mortality around 20%.⁷ Indeed, multiple series have reported an increasing trend for this indicator in several developed countries such as France,⁵ Italy⁴ or England.⁸ On the other hand, Finland⁹ and Sweden¹⁰ showed no significant changing trends, while Toyoda *et al*⁶ concluded that the mortality rate due to IE decreased in the United States of America between 1998 and 2013. Nevertheless, intrahospital mortality for IE is high, as reported in international series with 12.6% in the Euro Heart Survey,¹¹ 18% in the ICE study,¹² or 17.1% in the recent EURO-ENDO registry.¹³

Portugal has had a significant reduction in the mortality attributed to cardiovascular disease¹⁴ in all age groups in the last 20 years, predominantly related to a reduction in death attributed to ischemic heart disease. However, there is scarce data available regarding IE-related mortality.¹⁵

In this study, we aimed to address this lack of data in Portugal, with a population-based analysis involving fatal IE and to specifically evaluate temporal trends, age and gender differences.

MATERIAL AND METHODS

Study design and data source

A nationwide retrospective observational study on fatal IE was performed using data from the National Institute of Statistics (Instituto Nacional de Estatística – INE) in Portugal, from January 2002 to December 2018. All data used in this study is publicly available and was obtained directly from the INE's internet portal (https://www.ine.pt/xportal/xmain?xpgid=ine_main&xpid=INE&xlang=pt) or through the use of the email info@ine.pt for data request.

This data is based on information used for statistical purposes from the Civil Registry Integrated System (*Sistema Integrado do Registo e Identificação Civil* - SIRIC) and the Death Certificate Information System (*Sistema de Informação dos Certificados de Óbito* - SICO), covering all deaths, residents and non-residents, occurring in the country.

The death certificate is mandatory by law and is issued by a trained physician identifying the main cause of death and other secondary clinical diagnoses that contributed to death. For the studied period, only the basic clinical diagnosis causing death (“illness or injury that initiated the chain of pathological events that led to death or the circumstances of the accident or violence that produced the fatal injury”) could be collected.

After 2002, the coding of causes of death according to the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) version has been used and is carried out by the Portuguese Directorate-General of Health.¹⁶

For the identification of IE as the cause of death, we used codes I33, I38 and I39 (ICD-10).

Study population and variables

The population in each year was obtained from census population (2001 and 2011) and from estimates for intercensal years, at INE's database. The estimated population was 10 444 592 in 2002, increasing to 10 573 479 in 2009 and decreasing to 10 276 617 in 2018.¹⁷

Portuguese national all-cause mortality data for the period 2002 - 2018 was also obtained from INE,¹⁸ the number of deaths varied between 102 363 (2006) and 113 573 (2018), with the crude mortality rate varying between 9.69 (2006) and 10.99 (2018) per 1000 habitants.

All deaths caused by IE were assessed and stratified by gender and age groups (20-year interval groups, 0 - 19, 20 - 39, 40 - 59, 60 - 79, ≥ 80). Death location (healthcare institution vs home) was also collected, as well as data on whether medical autopsy was carried out.

The following indicators were analyzed: proportion of deaths with IE as cause of death (% of total deaths by specific cause); gender; location of death (healthcare institution vs home); crude death rate by gender and 20-year interval age groups; standardized mortality rate (all ages) for the European 2013 standard population¹⁹ performed by the direct method.²⁰

The study used anonymized public domain data and therefore ethics committee approval was not required.

Statistics

Continuous variables are presented as mean ± standard deviation and categorical variables expressed as frequencies and percentages. We assessed the trends in annual death rate standardized to the 2013 census population.

To assess temporal trends and the effect of age, gender and seasonality, we compared different regression models, including Poisson, negative binomial and corresponding zero-inflation regression models. We used Akaike's information criteria to compare different model structures and likelihood ratio tests to compare nested models with different covariates.²¹ We used 'age group', gender', 'month' and 'season' as potential covariates. The regression results are presented using rate ratios and corresponding 95% confidence intervals (CI).

The data was analyzed using IBM SPSS Statistics for Windows version 24, except for the regression models that were done with R,²² with the following packages MASS²² for the negative binomial models and pscl²³ for zero-inflated models.

RESULTS

Demographic features of patients who died of IE in Portugal

From 2002 to 2018, IE was documented as the cause of death in 3634 patients. Demographic data is depicted in Table 1.

Fatal cases of IE were lowest in the group ≤ 19 years old and increased with increasing patient age, with 89% of the deaths occurring in individuals 60 years old and older.

A growing number of deaths among patients with at least 60 years of age was noted throughout the 17-year study period, with a higher increase noted from 2010 onwards in patients 80 years old and over, exceeding those aged 60 - 79 years old (Fig. 1).

Of the total deaths, 1624 (44.7%) were males (M) and 2010 (55.3%) were females (F) and the *ratio* male/female was on average 0.84 (min. 0.62 – max. 1.1) per year, during the study period.

Among individuals 60 years of age and older, there were more female than male deaths, while the opposite was noted amongst younger patients (Fig. 2).

Mortality by IE in Portugal

IE was responsible on average for 2 out of 1000 deaths in Portugal, during the study period.

The standardized mortality (using the European 2013 standard population) rate due to IE in Portugal was on average 2.1 per 100 000 habitants, with an increasing trend for the period analyzed from 1.0 (2002) to 3.8 (2018) per 100 000 habitants (Fig. 3).

The proportion of deaths per IE to the total number of deaths of circulatory disease increased from 0.3 in 2002 to 1.2 in 2018. These results were driven by a reduction in the total number of deaths resulting from circulatory diseases in general (mortality rate due to circulatory diseases was 391 per 100 000 habitants in 2002 and decreased to 318 per 100 000 habitants in 2018), in line with an increase in the number of deaths by IE in the same period (Table 2).

Additionally, considering all years, men had a lower mortality rate for IE (1.9) than female patients (2.2). However, this difference between male and female patients only became clear over the last decade (Fig. 4 and Table 2).

IE specific mortality rate was lower in younger patients and increased gradually with age (Table 3). Comparing deaths caused by IE with total deaths in the Portuguese population, the highest contribution of IE was in the group 60 - 79 years old, decreasing slightly in patients over 80 years old.

Mortality according to place of death

Analysis on the place of death indicates that 71.9% died in a healthcare institution and 22.9% died at home. The remaining 5.2% of cases did not have information on place of death. Regardless of the place, the percentage of death in women was higher (this difference was more pronounced when considering deaths at home) than in men. Across all age groups, deaths in healthcare institutions were more prevalent (Fig. 5).

Medical autopsy confirming the diagnosis was available only for 104 death certificates (2.9% of the total cohort).

Temporal and seasonal effects on the deaths by IE

To study the evolution of the number of deaths due to IE in Portugal, we tested different model structures (see Methods) with the dependent variable 'number of deaths' each month from 2002 to 2018. We evaluated the temporal trend over that period, as well as the effect of gender, age group and season. The best model structure was a negative binomial, although a Poisson regression model gave essentially the same rate ratio estimates. To analyze the effect of season, we first used a preliminary model with 'month' as covariate. We found that the number of deaths increased in December, January, February and March, compared with the other months. Therefore, we defined two 'seasons': a winter period including those months, and the rest of the year. This shorter model was as good as the full model with individual months. The results of this regression are presented in Table 4.

The final variables included in the model, 'year', 'age group', 'gender' and 'season', were all highly significant and models without any one of these were statistically inferior, using a likelihood ratio test. We found an approximate 9% increase in incidence per year, since 2002. This estimate had very narrow confidence intervals. Women had a 19% higher incidence of death compared to men. The incidence increased substantially with older age groups, and this was very significant, despite wide confidence intervals in these estimates. Finally, we found a lower incidence (of approximately 20%) during the warmer months of the year, from April to November.

DISCUSSION

This is the first nationwide study analyzing deaths associated with IE in Portugal and four main findings were obtained from this analysis. First, the standardized mortality rate for IE was 2.1 per 100 000 inhabitants, with an annual increasing trend. Second, most deaths occurred in patients who were at least 60 years old. Third, there were more deaths of female

patients than male patients. Finally, mortality by IE was higher during the colder months.

The overall IE standardized mortality rate increased steadily from 1 to 3.8 per 100 000 people over the period of the study, 2002 to 2018. Data obtained from Instituto Nacional de Estatística revealed a consistent increase in IE specific mortality over this period, with an annual increase averaging about 9%. As a comparison, IE incident death rate in Finland²⁴ was lower (1.42 per 100 000 habitants) and there was no significant changing trend between 2004 and 2016. The incidence of IE in Portugal has not been estimated, and if it is increasing, it could be an important aspect helping to explain the increase seen in mortality. This is especially important, because nationwide studies from Denmark²⁵ and Italy⁴ have shown an increasing incidence of IE, which could impact on mortality. This increased incidence could be explained by several factors including ageing of the population, a higher use of intracardiac devices, cardiac valve prosthesis implantation and invasive medical procedures in a population with more comorbidities. A more debilitated population with IE could account for an increase in deaths by this disease. Likewise, the present analysis included a timeframe with significant changes in IE prophylaxis, improvement in IE diagnosis with newer techniques (improved microbiologic detection, 3D echocardiography and PET/CT imaging) and surgical intervention timing²⁶ that could have impacted on the mortality of these patients. Note that a dramatic decrease in Portugal's cardiovascular disease mortality and years of life lost has been demonstrated^{27,28} (this is due to diagnostic and therapeutic improvements of ischemic heart disease and cerebrovascular disease), which translated in a decrease in mortality due to circulatory diseases in the studied period, contrasting with an increasing trend in the mortality by endocarditis.

Despite deaths caused by IE occurring in all considered age groups, almost 90% of the deceased were 60 years old or older, which is in agreement with other series^{4,12,13,29-32} and from 2010 onwards octogenarians were in fact the most prevalent age-group. The elderly present more comorbidities, more heart valve disease and valve implants,^{33,34} are subject to more invasive medical procedures, are less likely to undergo cardiac surgery³⁵ and age has been shown to be an independent risk factor for mortality³⁶ in IE.

All these findings could partly be explained by Portuguese demographic trends. Indeed, the population in Portugal has experienced a gradual increase in life expectancy^{37,38} with a sustained increase in the aging index of the population,³⁹ with concomitant exacerbation of the comorbidities due to population aging.

Worldwide, in population-based studies of incident IE,⁴⁰ men are usually more affected. Paradoxically, in our study, women who have a higher life expectancy³⁷ (in Portugal, women live on average six years longer than men) and are also in greater number in the Portuguese population,¹⁷ had a higher mortality in the setting of IE with a *ratio* male/female varying between 0.6 and 1.1 - this comparison is more pronounced in older patients (over 60 years of age). This is probably explained by the fact that gender may, indeed, be an additional risk factor for IE mortality.^{13,32,41} Moreover, gender variations regarding comorbidities, frailty index, treatment biases and physiologic differences may explain this contradictory finding.⁴²

Nearly 3% of patients that died due to IE underwent a medical autopsy – indeed, autopsy continues to be an important tool in identifying clinically missed IE and in unveiling the multisystemic involvement and complications that may emerge from IE. Nevertheless, hospital series report fatal IE cases in 1% - 1.5% of autopsies,^{43,44} meaning that only a minor fraction of cases are diagnosed after death occurs. Despite a paucity of data regarding the frequency which IE is found in autopsies,⁴⁴ it is a crucial method of clinical research. Nearly 23% of subjects died at home, which is unexpected as IE is a complex disease with almost universal hospitalization, and the number of autopsies is clearly lower than this rate. Newly diagnosed fatal IE with sudden death identified in an autopsy is one explanation. Data concerning previous hospitalization, or the treatment regimen, was not available and therefore the reasons that could potentially explain the remaining cases are speculative. Still, this finding could be related to patients with a very recent hospitalization for acute IE, on outpatient parenteral antibiotic course, or waiting for cardiac surgery, or in patients that were referred for palliative care.

A 2017 meta-analysis⁴⁵ including twenty five observational studies, estimated short and long term follow-up (six months up to 10 years) mortality rate of 20% and 37%, respectively. Data on long term outcomes of IE in population-based and observational studies are limited – the 5-year mortality rate described by Fernandez-Hidalgo *et al*⁴⁶ and Toyoda *et al*⁴⁷ was around 50%. Alarmingly, long-term outcomes have shown to be poor, even in patients who have survived and have been discharged from hospital after an IE event.⁴⁸ This may probably explain why we have found that one fifth of deaths occurred outside a healthcare institution. Other factors that could partially contribute to this high rate is the diagnosis of IE through autopsy in deaths occurring outside a hospital.

Finally, there is scarce data on the impact of seasonal variation on deaths for IE.⁴⁹ Indeed, seasonal mortality variation has been described in other conditions such as heart failure,^{50,51} sepsis,⁵² cardiovascular and all-cause mortality.^{53,54} In our study, a 20% mortality decrease was noted during the warmer months. Reasons for this result remain speculative, but should take into account not only exposure to cold, but also socio-economic conditions,⁵⁵ or immunologic response with cold temperatures related to melatonin secretion⁵⁶ and leukocyte function.⁵⁷ Finkelhor⁵⁸ detected a higher fall/winter predominance of the diagnosis of IE with echocardiography, with an impact on incidence and, possibly, mortality as well.

Limitations of the study

One must consider that this is a retrospective study based on administrative data using coded information. Reliable

and uniform diagnosis is always an issue. Coding errors could also have occurred, and there is no possibility to review clinical data, case by case. Nevertheless, death certificates are issued by trained physicians, which guarantees the quality of the presented data. Furthermore, no data exists concerning the population with IE and its characteristics such as demographics, comorbidities, microbiology, procedures or surgical interventions that could help explain our findings regarding mortality rate and its temporal trends. Additionally, codes I38 and I39 can include non-infective forms of IE such as Libmann-Sachs. Finally, as previously mentioned, there is currently no published data on the incidence of IE incidence in Portugal, which would be crucial for this discussion.

CONCLUSION

IE has a mortality rate estimated at 2.1 per 100 000 people, with an increasing trend of around 9% annually. A seasonal variation was noted, with increased mortality in the colder months. The association of IE with death was more significant in older patients, particularly in those aged 60 years old or older, and women had a higher IE specific mortality rate. Portuguese demographic features can partially explain the observed outcomes. Further analysis of the epidemiology of IE in Portugal, especially incidence of the disease, previous comorbidities and demographics of the patients, as well as other socio-economic factors such as level of education and income would be crucial to expand our understanding of these findings.

ACKNOWLEDGEMENTS

The authors would like to thank the Instituto Nacional Estatística for providing Portuguese demographic data and IE specific mortality data. The authors also acknowledge the reviewers' suggestions that improved the manuscript.

PROTECTION OF HUMANS AND ANIMALS

The authors declare that the procedures were followed according to the regulations established by the Clinical Research and Ethics Committee and to the Helsinki Declaration of the World Medical Association updated in 2013.

DATA CONFIDENTIALITY

Patients were not directly studied, and their informed consent was not deemed necessary because the data collected was retrospective and immediately anonymized.

COMPETING INTERESTS

The authors do not have any conflict of interests concerning the content of this article.

FUNDING SOURCES

This study has not received any public or private funding.

REFERENCES

- Habib G, Lancellotti P, Antunes M, Bongiorni M, Casalta JP, Del Zotti F, et al. 2015 ESC guidelines for the management of infective endocarditis. *Eur Heart J*. 2015;36:3075–128.
- Cahill T, Prendergast B. Infective endocarditis. *Lancet*. 2016;387:882–93.
- Heredia-Rodríguez M, Hernández A, Bustamante-Munguira J, Álvarez F, Eiros J, Castrodeza J, et al. Evolution of the incidence, mortality, and cost of infective endocarditis in Spain between 1997 and 2014. *J Gen Intern Med*. 2018;33:1–4.
- Cresti A, Chiavarelli M, Scalese M, Nencioni C, Valentini S, Guerrini F, et al. Epidemiological and mortality trends in infective endocarditis, a 17-year population-based prospective study. *Cardiovasc Diagn Ther*. 2017;7:27–35.
- Thuny F, Giorgi R, Habachi R, Ansaldi S, Le Dolley Y, Casalta J, et al. Excess mortality and morbidity in patients surviving infective endocarditis. *Am Heart J*. 2012;164:94–101.
- Toyoda N, Chikwe J, Itagaki S, Gelijns A, Adams D, Egorova N. Trends in infective endocarditis in California and New York State, 1998–2013. *J Am Med Assoc*. 2017;317:1652–60.
- Thuny F, Grisoli D, Collart F, Habib G, Raoult D. Management of infective endocarditis : challenges. *Lancet*. 2012;379:965–75.
- Mark JD, Jones S, Prendergast B, Baddour L, Lockhart P, Thornhill M. An increase in the incidence of infective endocarditis in England since 2008 : a secular trend interrupted time series analysis. *Lancet*. 2015;385:1219–28.
- Ahtela E, Oksi J, Porela P, Ekström T, Rautava P, Kytö V. Trends in occurrence and 30-day mortality of infective endocarditis in adults: population-based registry study in Finland. *BMJ Open*. 2019;9:e026811.
- To A, Ternhag A, Cederstro A. A nationwide cohort study of mortality risk and long-term prognosis in infective endocarditis in Sweden. *PLoS One*. 2013;8:1–7.
- Tornos P, lung B, Permanyer-Miralda G, Baron G, Delahaye F, Gohlke-Bärwolf C, et al. Infective endocarditis in Europe: lessons from the euro heart survey. *Heart*. 2005;91:571–5.
- Murdoch DR, Corey GR, Hoen B, Miró JM, Pappas PA, Moreillon P, et al. NIH Public Access: Clinical presentation, etiology and outcome of infective endocarditis in the 21st century: the international collaboration on endocarditis-prospective cohort study. *Arch Intern Med*. 2013;169:463–73.
- Habib G, Erba PA, lung B, Donal E, Cosyns B, Laroche C, et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. *Eur Heart J*. 2019;40:3222–32.
- Nascimento BR, Brant LC, Oliveira MG, Malachias MV, Reis GM, Teixeira RA, et al. Epidemiologia das doenças cardiovasculares em países de língua. *Arq Bras Cardiol*. 2018;110:500–11.
- Antunes M, Saraiva J. Is the role of surgery in infective endocarditis changing? *Rev Port Cardiol*. 2018;37:395–7.
- Instituto Nacional de Estatística. Causas de morte -2017. 2019. [cited 2020 May 1]. Available from: https://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_

- publicacoes&PUBLICACOESpub_boui=358633033&PUBLICACOESmodo=2.
17. Instituto Nacional de Estatística. Estimativas da população residente Portugal, NUTSII, NUTS III. 2009. [cited 2020 May 5]. Available from: https://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_publicacoes&PUBLICACOESTipo=ea&PUBLICACOEScoleccion=107818&PUBLICACOESTema=55466&selTab=tab0&xlang=pt.
 18. Instituto Nacional de Estatística. Óbitos (N.º) por local de residência (NUTS - 2013), grupo etário e sexo; Anual. INE. [cited 2020 May 5]. Available from: https://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_indicadores&indOcorrCod=0004204&contexto=bd&selTab=tab2&xlang=pt.
 19. Eurostat. Revision of the European standard population - Report of Eurostat's task force. Luxembourg: Eurostat; 2013. 20.
 20. Tripepi G, Jager J, Dekker F. Stratification for confounding – Part 2 : direct and indirect standardization. *Nephron Clin Pract.* 2010;116:c322-5.
 21. Hu MC, Pavlicova M, Nunes EV. Zero-inflated and hurdle models of count data with extra zeros: examples from an hiv-risk reduction intervention trial. *Am J Drug Alcohol Abuse.* 2011;37:367-75.
 22. Team RC. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. 2018. [cited 2020 May 03]. Available from: <https://www.R-project.org/>.
 23. Zeileis A, Kleiber C, Jackman S. Regression models for count data in R. *J Stat Softw.* 2008;27:1-25.
 24. Ahtela E, Oksi J, Sipilä J, Rautava P, Kytö V. Occurrence of fatal infective endocarditis: a population-based study in Finland. *BMC Infect Dis.* 2019;19:1-7.
 25. Erichsen P, Gislason G, Bruun N. The increasing incidence of infective endocarditis in Denmark, 1994 – 2011. *Eur J Intern Med.* 2016;35:95-9.
 26. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vlacosta I, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): The Task Force on the Prevention, Diagnosis, and Treatment of infective endocarditis of the European Society of Cardiology (ESC). *Eur Heart J.* 2009;30:2369-413.
 27. Pereira M, Azevedo A, Lunet N, Carreira H, O'Flaherty M, Capewell S, et al. Explaining the decline in coronary heart disease mortality in Portugal between 1995 and 2008. *Circ Cardiovasc Qual Outcomes.* 2013;6:634-42.
 28. Pereira M, Peleteiro B, Capewell S, Bennett K, Azevedo A, Lunet N. Changing patterns of cardiovascular diseases and cancer mortality in Portugal, 1980-2010. *BMC Public Health.* 2012;12:1126.
 29. Fedeli U, Schievano E, Buonfrate D, Pellizzer G, Spolaore P. Increasing incidence and mortality of infective endocarditis: a population-based study through a record-linkage system. *BMC Infect Dis.* 2011;11:1-7.
 30. Selton-Suty C, Celard M, Le Moing V, Doco-Leconte T, Chirouze C, Lung B, et al. Preeminence of staphylococcus aureus in infective endocarditis : a 1-year population-based survey. *Clin Infect Dis.* 2012;54:1230-9.
 31. Duval X, Delahaye F, Alla F, Tattevin P, Obadia J, Moing V, et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications three successive population-based surveys. *J Am Coll Cardiol.* 2012;59:1968-76.
 32. Van Den Brink F, Swaans M, Hoogendijk M, Alipour A, Kelder J, Jaarsma W, et al. Increased incidence of infective endocarditis after the 2009 European Society of Cardiology guideline update: a nationwide study in the Netherlands. *Eur Hear J Qual Care Clin Outcomes.* 2017;3:141-7.
 33. Nkomo V, Gardin J, Skelton T, Gottdiener J, Scott C, Enriquez-Sarano M. Burden of valvular heart diseases : a population-based study. *Lancet.* 2006;368:1005-11.
 34. Dhawan V. Infective endocarditis in elderly patients. *Clin Infect Dis.* 2002;34:806-12.
 35. Ramírez-Duque N, García-Cabrera E, Ivanova-Georgieva R, Noureddine M, Lomas JM, Hidalgo-Tenorio C, et al. Surgical treatment for infective endocarditis in elderly patients. *J Infect.* 2011;63:131-8.
 36. Durante-Mangoni E. Current features of infective endocarditis in elderly patients. *Arch Intern Med.* 2008;168:2095.
 37. Instituto Nacional de Estatística. Tábuas de mortalidade 2014 - 2016. Informação à comunicação social. Lisboa: INE; 2017.
 38. Instituto Nacional de Estatística. Projeções de população residente 2015-2080. Lisboa: INE; 2017.
 39. Instituto Nacional de Estatística. Projeções de população residente 2002-2060. Lisboa: INE; 2014.
 40. Scott C, Bailey K, Steckelberg J. A systematic review of population-based studies of infective endocarditis. *Chest.* 2007;132:1025-35.
 41. Khan M, Munir M, Khan M, Khan S, Benjamin M, Balla S. Contemporary trends in native valve infective endocarditis in united states (from the national inpatient sample database). *Am J Cardiol.* 2020;125:1678-87.
 42. Aksoy O, Meyer L, Cabell C, Kourany W, Pappas P, Sexton D. Gender differences in infective endocarditis: Pre- and co-morbid conditions lead to different management and outcomes in female patients. *Scand J Infect Dis.* 2007;39:101-7.
 43. Zhou Y, Wilkinson S, Cain M, Litovsky S, Reilly S. A 12-year autopsy review of infective endocarditis. *Am J Clin Pathol.* 2012;138:A260.
 44. Guerrero M, Álvarez B, Manzarbeitia F, Renedo G. Infective endocarditis at autopsy: a review of pathologic manifestations and clinical correlates. *Medicine.* 2012;91:152-64.
 45. Abegaz T, Bahagavathula A, Gebreyohannes E, Mekonnen A, Abebe T. Short-and long-term outcomes in infective endocarditis patients: a systematic review and meta-analysis. *Cardiovasc Disord.* 2017;17:1-12.
 46. Fernández-Hidalgo N, Almirante B, Tornos P, González-Alujas M, Planes A, Galiñanes M, et al. Immediate and long-term outcome of left-sided infective endocarditis. A 12-year prospective study from a contemporary cohort in a referral hospital. *Clin Microbiol Infect.* 2012;18:e522-30.
 47. Toyoda N, Chikwe J, Itagaki S, Gelijns A, Adams D, Egorova N. Trends in infective endocarditis in California and New York state, 1998-2013. *JAMA.* 2017;317:1652-60.
 48. Shih C, Chu H, Chao P, Lee Y, Kuo S, Li SY, et al. Long-term clinical outcome of major adverse cardiac events in survivors of infective endocarditis a nationwide population-based study. *Circulation.* 2014;130:1684-91.
 49. Chen S, Chao T, Lin Y, Lo LW, Hu Y, Tuan T, et al. Cool seasons are related to poor prognosis in patients with infective endocarditis. *Int J Biometeorol.* 2012;56:973-81.
 50. Boulay F, Berthier F, Sisteron O, Gendreau Y, Gibelin P. Seasonal variation in chronic heart failure hospitalizations and mortality in France. *Circulation.* 1999;100:280-6.
 51. Martínez-Sellés M, Robles J, Prieto L, Serrano J, Muñoz R, Frades E, et al. Annual rates of admission and seasonal variations in hospitalizations for heart failure. *Eur J Heart Fail.* 2002;4:779-86.
 52. Danai P, Sinha S, Moss M, Haber M, Martin G. Seasonal variation in the epidemiology of sepsis. *Crit Care Med.* 2007;35:410-5.
 53. Marti-Soler H, Gonseth S, Gubelmann C, Stringhini S, Bovet P, Chen PC, et al. Seasonal variation of overall and cardiovascular mortality: a study in 19 countries from different geographic locations. *PLoS One.* 2014;9:1-13.
 54. Rau R, Bohk-Ewald C, Muszyńska M, Vaupel J. Seasonality of causes of death. In: Rau R, Bohk-Ewald C, Muszyńska MM, Vaupel JW, editors. *Visualizing mortality dynamics in the lexis diagram.* Berlin: Springer. 2018; p. 99-122.
 55. Oestergaard L, Schmiegelow M, Bruun N, Skov R, Petersen A, Andersen P, et al. The associations between socioeconomic status and risk of staphylococcus aureus bacteremia and subsequent endocarditis – a Danish nationwide cohort study. *BMC Infect Dis.* 2017;17:589.
 56. Dowell SF. Seasonal variation in host susceptibility and cycles of certain infectious diseases. *Emerg Infect Dis.* 2001;7:369-74.
 57. Demas G, Bartness T, Nelson R, Drazen D. Photoperiod modulates the effects of norepinephrine on lymphocyte proliferation in Siberian hamsters. *Am J Physiol Regul Integr Comp Physiol.* 2003;285:R873-9.
 58. Finkelhor R, Cater G, Qureshi A. Seasonal diagnosis of echocardiographically demonstrated endocarditis. *Chest.* 2005;128:2588-92.

Table 1 – Demographic characteristics of patients with fatal IE between 2002- 2018, in Portugal

Characteristics	n (%)
Gender	
Male	1624 (44.7)
Female	2010 (55.3)
Age (years)*	
≤ 19	2 (0.05)
20 - 39	66 (1.8)
40 - 59	316 (8.7)
60 - 79	1534 (42)
≥ 80	1715 (47)
ICD 10	
I33 – Acute and subacute endocarditis	734 (20.2)
I38 – Non specified valve endocarditis	2899 (79.8)
I39 – Endocarditis and valve changes	1 (0.0)

* One case of unknown age

Table 2 – Total and gender specific mortality (absolute and rate) by infective endocarditis between 2002 and 2018, in Portugal

Year	Number of deaths by IE	Mortality rate for IE*	Number of deaths by circulatory causes	Mortality rate for circulatory causes*	Proportion deaths by IE to circulatory causes	Number of deaths by IE (male)	Male specific mortality rate by IE*	Number of deaths by IE (female)	Female specific mortality rate by IE*
2002	106	1.01	40 846	391.07	0.26	48	0.95	58	1.07
2003	110	1.05	40 893	390.46	0.27	59	1.17	51	0.94
2004	106	1.01	36 983	352.40	0.29	51	1.01	55	1.01
2005	141	1.34	36 570	347.89	0.39	61	1.21	80	1.47
2006	108	1.03	32 872	312.10	0.33	54	1.07	54	0.99
2007	154	1.46	34 103	323.15	0.45	69	1.36	85	1.55
2008	165	1.56	33 642	318.49	0.49	82	1.62	83	1.51
2009	199	1.88	33 314	315.07	0.60	88	1.74	111	2.01
2010	189	1.79	33 693	318.68	0.56	88	1.74	101	1.83
2011	210	1.99	31 565	299.41	0.67	97	1.92	113	2.05
2012	230	2.19	32 761	312.39	0.70	105	2.09	125	2.27
2013	280	2.69	31 421	301.33	0.89	119	2.39	161	2.94
2014	275	2.65	32 134	309.73	0.86	126	2.55	149	2.73
2015	296	2.86	32 275	312.10	0.92	114	2.32	182	3.34
2016	343	3.33	32 628	316.48	1.05	150	3.07	193	3.55
2017	332	3.23	32 180	312.70	1.03	140	2.87	192	3.54
2018	390	3.80	32 732	318.51	1.19	173	3.56	217	4.00

* Per 100 000 persons

Table 3 – Age specific proportion of deaths caused by IE per total number of deaths and IE mortality rate

Age group	n	Proportion IE deaths per total deaths (*100)	Age specific IE mortality rate*
≤ 19	2	0.02	< 0.0001
20 - 39	66	0.17	0.13
40 - 59	316	0.18	0.64
60 - 79	1534	0.24	4.30
≥ 80	1715	0.18	17.92

* Per 100 000 persons per year

Table 4 – Results of negative binomial regression for the number of monthly deaths

Variable	Rate ratio	Lower limit	Upper limit	p-value
Baseline	0.048	0.036	0.065	
Year*	1.086	1.077	1.094	< 0.00001
Age [0, 39]	1			< 0.00001
[40, 59]	9.4	7.3	12.4	
[60, 79]	45.5	35.9	58.8	
≥ 80	48.7	38.4	62.9	
Gender Male	1			< 0.00001
Female	1.19	1.10	1.28	
Season†	1			< 0.00001
	0.797	0.737	0.862	

* Year is coded as a continuous variable from 1 to 17, corresponding to 2002 to 2018; † The reference season is from December to March.




Figure 1 – Distribution of fatal IE cases by age group from 2002 to 2018




Figure 2 – Distribution of patients with fatal IE according to age and gender




Figure 3 – Evolution of deaths due to IE in Portugal from 2002 to 2018. Standardized mortality rate (per 100 000) (purple line) and proportion of deaths (%) that are due to IE in relation to all circulatory diseases (green – dashed line).




Figure 4 – Evolution from 2002 to 2018 of specific cause of death (IE) standardized mortality rate by gender in Portugal




Figure 5 – Distribution of patients concerning death location according to gender (A) and age group (B)

ARTIGO ORIGINAL
ARTIGO ACETITE PARA PUBLICAÇÃO DISPONÍVEL EM WWW.ACTAMEDICAPORTUGUESA.COM